標(biāo)題: Titlebook: Neurophysiologic Biomarkers in Neuropsychiatric Disorders; Etiologic and Treatm Daniel C. Javitt,James C. McPartland Book 2024 The Editor(s [打印本頁] 作者: Gullet 時(shí)間: 2025-3-21 16:36
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders影響因子(影響力)
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders影響因子(影響力)學(xué)科排名
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders網(wǎng)絡(luò)公開度
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders被引頻次
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders被引頻次學(xué)科排名
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders年度引用
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders年度引用學(xué)科排名
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders讀者反饋
書目名稱Neurophysiologic Biomarkers in Neuropsychiatric Disorders讀者反饋學(xué)科排名
作者: 門閂 時(shí)間: 2025-3-21 21:03 作者: 效果 時(shí)間: 2025-3-22 02:35
Book 2024use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, mo作者: 思鄉(xiāng)病 時(shí)間: 2025-3-22 07:06 作者: hauteur 時(shí)間: 2025-3-22 10:16
Biomarker Methodologies: A NIMH Perspectiveel interventions. This chapter highlights examples of biomarker technologies that have been utilized to advance understanding of the pathophysiology of psychiatric disorders and the development of novel therapeutics.作者: Intractable 時(shí)間: 2025-3-22 16:45 作者: 痛苦一生 時(shí)間: 2025-3-22 18:10
Rodent Models for ASD Biomarker Developmented by current knowledge of genetics, molecular biology, and bioinformatics. These ASD-associated rodent models enable quantifiable biomarker development. Finally, we discuss the prospects of ASD biomarker development.作者: cartilage 時(shí)間: 2025-3-23 00:57
The Use of Event-Related Potentials in the Study of Schizophrenia: An Overview leading hypotheses about the pathophysiology of schizophrenia. We conclude with an evaluation of both the utility and limitations of ERPs in schizophrenia research and offer recommendations of future directions that may be beneficial to the field.作者: Coronary-Spasm 時(shí)間: 2025-3-23 03:58
Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Devidence for this hypothesis is critically reviewed, focusing on studies in the areas of visual feature binding, auditory steady-state response, and spontaneous gamma activity. The current state of the field is discussed, and recommendations for future directions are presented.作者: CHECK 時(shí)間: 2025-3-23 09:13 作者: Oratory 時(shí)間: 2025-3-23 11:23 作者: 證明無罪 時(shí)間: 2025-3-23 15:44 作者: Firefly 時(shí)間: 2025-3-23 20:39
Neurophysiologic Biomarkers in Neuropsychiatric Disorders978-3-031-69491-2Series ISSN 2190-5215 Series E-ISSN 2190-5223 作者: abreast 時(shí)間: 2025-3-24 00:15
Daniel C. Javitt,James C. McPartlandOffers a comparative review of biomarkers across major mental health disorders.Discusses applications to drug development via the 21st Century Cares Act.Presents a translational approach to appeal to 作者: orthopedist 時(shí)間: 2025-3-24 02:50 作者: 期滿 時(shí)間: 2025-3-24 07:37
Neural Circuitry-Related Biomarkers for Drug Development in Psychiatry: An Industry Perspectiveies in identifying patient subsets more amenable to benefit from a given asset, and issues with executing trials in a manner that would convincingly provide answers. An emerging idea in many companies is to validate tools to address changes in neural circuits by pharmacological tools as a key piece 作者: Infant 時(shí)間: 2025-3-24 13:04
Public–Private Partnerships for Neuropsychiatric Drug Development: A Perspective. To date, however, progress has been limited in part because of the limited nature of the studies and the absence of the types of large-scale networks that would be required for clinical validation. The first public–private partnership (PPP) for biomarker validation—the Alzheimer’s Disease Neuroima作者: Dictation 時(shí)間: 2025-3-24 15:38
Methods for and Use of Functional Magnetic Resonance Imaging in Psychiatryependent (BOLD) signal. Over the 30+ years since the technique was first described (Ogawa et al. 1990), BOLD-fMRI has uncovered much about the organization and function of the human brain and is now beginning to fulfill its promise as a tool for diagnostic and prognostic biomarker of psychiatric con作者: 慢慢啃 時(shí)間: 2025-3-24 19:13
Advanced Methodology for Neurophysiological Analysis and Biomarker Development: Time–Frequency and Seen preclinical animal models and clinical human studies. Neurophysiological measures, especially event-related potentials (ERP), provide effective physiological read-outs of the flow of information from primary sensory through higher-order associative brain regions and thus can be used to investiga作者: 陰郁 時(shí)間: 2025-3-25 02:12 作者: gregarious 時(shí)間: 2025-3-25 05:57 作者: surrogate 時(shí)間: 2025-3-25 10:06
Rodent Models for ASD Biomarker Development biochemical, anatomical, and electrophysiological measures are emerging as potential disease-relevant biomarkers that could inform the diagnosis and clinical management of ASD. Rodent ASD models play a key role in ASD research as essential experimental tools. Nevertheless, there are challenges and 作者: Morose 時(shí)間: 2025-3-25 11:41 作者: STING 時(shí)間: 2025-3-25 16:13
Functional Connectivity Biomarkers in Schizophreniapite over 100?years of study, the treatment for schizophrenia remains limited, partially due to the lack of knowledge about the neural mechanisms of the illness and how they relate to symptoms. The US Food and Drug Administration (FDA) and the National Institute of Health (NIH) have provided seven b作者: ANTE 時(shí)間: 2025-3-25 20:51 作者: jeopardize 時(shí)間: 2025-3-26 02:11 作者: CANE 時(shí)間: 2025-3-26 08:17 作者: hardheaded 時(shí)間: 2025-3-26 10:08 作者: faucet 時(shí)間: 2025-3-26 15:19
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Irments associated with schizophrenia (CIAS) are key features of the disorder and primary predictors of long-term disability. At the neurochemical level, both CIAS and negative symptoms are potentially attributable to dysfunction or dysregulation of N-methyl-.-aspartate receptor (NMDAR)-mediated neur作者: AGGER 時(shí)間: 2025-3-26 18:29 作者: ABOUT 時(shí)間: 2025-3-27 00:20
Patricio O’Donnell,Derek L. Buhl,Jason Johannesen,Marijn Lijffijts a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: 天空 時(shí)間: 2025-3-27 04:57
William Z. Potters a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: 青少年 時(shí)間: 2025-3-27 05:39 作者: Bureaucracy 時(shí)間: 2025-3-27 10:22
Pejman Sehatpour,Daniel C. Javitts a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: 寵愛 時(shí)間: 2025-3-27 13:37
Angelantonio Tavella,Peter J. Uhlhaass a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: 腐蝕 時(shí)間: 2025-3-27 18:48 作者: GEN 時(shí)間: 2025-3-27 22:13
Henry H. C. Lee,Mustafa Sahins a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: Femish 時(shí)間: 2025-3-28 04:12 作者: jettison 時(shí)間: 2025-3-28 07:36 作者: 金絲雀 時(shí)間: 2025-3-28 10:57 作者: Formidable 時(shí)間: 2025-3-28 14:48 作者: Blood-Vessels 時(shí)間: 2025-3-28 22:50
Ahmad Mayeli,Francesco L. Donati,Fabio Ferrarellis a large amount of new basic and clinical information.Contr.Translational medicine underpins vascular medicine. It is fundamental to understanding how we treat patients with vascular disease and more importantly, how to prevent it. It is the rationale for drug design and production. Vascular medici作者: 黑豹 時(shí)間: 2025-3-29 00:30 作者: tangle 時(shí)間: 2025-3-29 04:17 作者: Collision 時(shí)間: 2025-3-29 11:17
2190-5215 searchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development..978-3-031-69493-6978-3-031-69491-2Series ISSN 2190-5215 Series E-ISSN 2190-5223 作者: 冒失 時(shí)間: 2025-3-29 15:02
Margaret C. Grabb,Linda S. Bradyar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: 是他笨 時(shí)間: 2025-3-29 19:06
Patricio O’Donnell,Derek L. Buhl,Jason Johannesen,Marijn Lijffijtar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: Evocative 時(shí)間: 2025-3-29 23:43
William Z. Potterar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: 致命 時(shí)間: 2025-3-30 02:50 作者: Chivalrous 時(shí)間: 2025-3-30 05:07
Pejman Sehatpour,Daniel C. Javittar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: 失敗主義者 時(shí)間: 2025-3-30 10:54 作者: 暴行 時(shí)間: 2025-3-30 14:51
A. M. Rader Groves,C. G. Gallimore,J. P. Hammar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: 貞潔 時(shí)間: 2025-3-30 19:24
Henry H. C. Lee,Mustafa Sahinar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: 彈藥 時(shí)間: 2025-3-30 23:14
Monica N. O’Connell,Annamaria Barczakar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8作者: indubitable 時(shí)間: 2025-3-31 03:44
Amber M. Howell,Alan Anticevicar medicine. The book is based on the third vascular biology conference held at The Royal College of Physicians in 2008. It provides a large amount of new basic and clinical information and the contributors are world leaders..978-1-4471-5832-5978-0-85729-920-8
